Moreover, mutations of this receptor can lead to intrinsically active form of FGFR2 reported in endometrial and lung cancers.5 Inhibition of RTKs as a promising target in treatment of different kinds of cancers has been led to development of remarkable therapeutic agents.6 Most of these tyrosine kinase inhibitors (TKI) at different clinical phases are the small molecules targeting ATP-binding site of the kinase domain of RTKs.7 Here, FGFR2 is linked to cancer.